Skip to main content

Ascletis Starts China Bridging Trial of FXR Agonist for Hepatitis B

Ascletis Pharma of Hangzhou started a China bridging trial of its FXR agonist following a successful US Phase I trial of ASC42 in healthy patients. The China trial will also enroll healthy patients in a placebo-controlled, dose escalation trial. As an FXR agonist, ASC42 inhibits the transcription of chronic hepatitis B virus. In preclinical tests, the candidate showed promise as a cure for CHB. Ascletis developed ASC42 in-house and believes it has best-in-class potential. It is also being tested as a treatment for NASH. More details.... Stock Symbol: (HK: 1672) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.